Therefore, blocking MDM2-mediated TOP2β degradation by RG7112 synergistically suppresses lung cancer cell survival following treatment with VP-16, resulting in an increase in apoptosis and susceptibility to VP-16 treatment. Here, TOP2B is linked to lung cancer.